TP53 and gastrointestinal stromal tumor: Key molecular events, such as cyclin-dependent kinase inhibitor 2A (CDKN2A) loss, mouse double minute 2 homolog (MDM2) overexpression, and p53 inactivation, are critical in GIST progression [10].